Anlon Healthcare Limited has submitted an intimation to the stock exchanges regarding a media interaction by its Chairman & Managing Director, pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was filed on June 09, 2026.

Media Interaction Details

Mr. Punitkumar Rasadia, Chairman & Managing Director of Anlon Healthcare, participated in an interview that was aired and released on Money TV under the program titled "Result Analysis for You (RAY)". The key details of the interaction are outlined below:

Topics Covered

During the interaction, the discussion primarily covered the following areas:

• Financial performance for FY 2025-26
• Business developments of the company
• Industry outlook
• Other information already available in the public domain

Regulatory Compliance

Anlon Healthcare confirmed that no unpublished price sensitive information (UPSI) was shared during the interaction, ensuring full compliance with applicable SEBI regulations. The company has requested the exchanges to take the information on record.

The interview can be accessed through the following links:

• Money TV Website: https://moneytv.live/
• YouTube: https://www.youtube.com/watch?v=RnI7jniyII4

Anlon Healthcare Limited has reported its audited standalone and consolidated financial results for the financial year ended March 31, 2026, alongside an investor presentation for Q4 and FY26. The company recorded a 42.98% increase in consolidated total income to ₹172.22 crore, driven by strong operational performance and strategic acquisitions including Bizotic Lifescience and Apiqo Organics. The Board of Directors approved the results at a meeting held on May 29, 2026.

Financial Performance

For the financial year FY26, Anlon Healthcare achieved a consolidated total income of ₹172.22 crore, a rise from ₹120.46 crore in FY25. Revenue from operations for the year stood at ₹171.97 crore, compared to ₹120.29 crore in the prior year. The company's consolidated net profit for the period improved to ₹29.09 crore from ₹20.52 crore in the previous year. Consolidated EBITDA increased by 47.55% to ₹47.77 crore, with an EBITDA margin of 27.74%.

On a standalone basis for FY26, total income was recorded at ₹176.26 crore, while net profit for the year was ₹27.81 crore. Earnings per share (EPS) on a basic and diluted basis for the year were reported at ₹5.93. The statutory auditors, R V D & Co., provided an unmodified opinion on the standalone and consolidated annual financial results.

Q4FY26 Results

For the quarter ended March 31, 2026 (Q4FY26), the company reported a total income of ₹50.90 crore, compared to ₹48.97 crore in Q4FY25. Net profit for Q4FY26 stood at ₹11.07 crore, down from ₹16.65 crore in the corresponding quarter of the previous year. The EBITDA for the quarter was ₹15.31 crore, with a margin of 30.07%.

The following table summarises the key standalone financial metrics for FY26:

Key Developments

During the year, the company completed the acquisition of Bizotic Lifescience, which is now a subsidiary of Anlon Healthcare, strengthening its manufacturing platform. Apiqo Organics continues to strengthen backward integration capabilities. The company also continued development of 3 molecules for 2 global innovator companies under the CDMO business vertical and diversified into the Industrial & Fine Chemicals segment. The investor presentation highlights a combined installed capacity expected to reach 1,400–1,600 MTPA post expansion and plans for 3–5 DMF filings in FY 2026-27.

Board and Compliance

The filing was submitted in compliance with Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. A newspaper advertisement confirming the publication of these results was released on May 30, 2026. The investor presentation for Q4 & FY26 was uploaded on the company's website on June 03, 2026.